

REFERENCES

- Abo Al-Azm, A; and El-Sheikh, M; (1996):*** Prevalence of hepatitis C and B viruses in Gharbia Governorate rural area in comparison with a group of Blood donors. JHGID; 4 (4): 31-39.
- Abd El-Baset MZ, Lashin AH, Abo-Senna AA and Biomy HA (2006):*** Evaluation of liver fibrosis markers in chronic liver diseases". MD thesis in Banha Faculty of Medicine Results. Page 172-188.
- Abdel-Wahab MF, Zakaria S, Kamel M; Abdel-Khaliq, M.K; Mabrouk, M. A; Salama, H; Esmat, G; Thomas, D.L; and Thomas Stricklan, G; (1994):*** High seroprevalence of hepatitis C virus infection among risk groups in Egypt. Am. J. Trop. Med. Hyg.; 51(5):563-547.
- Abdi, W; Milla, J.C; and Mezey, E; (1979):*** Sampling variability on percutaneous liver biopsy. Arch. Intern. Med; 139: 667-669.
- Adler, M; Gulbis, B; Moreno, C; Evrard, S; Verset, G; Golstein, P; Frotscher, B; Nagy, N; and Thiry, P; (2008):*** The predictive value of FIB-4 versus FibroTest, APRI, fibro index and Forms index to non-invasively estimate fibrosis in hepatitis C and Non-hepatitis C liver diseases. Hepatology; 47 (2): 762-763.
- Afdhal, N.H; and Curry, M; (2007):*** Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J. Hepatol. 46: 543:545.

- Aguirre, D.A; Behling, C.A; Alpert, E; Hassanein, T.I; and Sirlin, C. B; (2006):** Liver fibrosis: non-invasive diagnosis in the double contrast material enhanced MR imaging radiology; 239: 425-437.
- Al-Ghamdi, A.S; (2007):** Fibroscan: A non invasive test of liver fibrosis assessment Soudi, J. Gastroenterol; 13: 147-9.
- Andersen,E.S; Christensen, P.B; and Weis, N; (2008):** Transient elastography for liver fibrosis diagnosis European journal of internal medicine; 20 (4): 339-342.
- Arena, U; Vizzutti, F; Corti, G; Ambw, S; Stasi, C; Bresci, S; Moscarella, S; Boddi, V; Petrarca, A; Laffi, F; Marra, F; and Pinzani, M; (2008):** Acute viral hepatitis increase liver stiffness values measured by transient elastography. Hepatology; 47: 380-384.
- Arthur, M.J; (2000):** Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol; 279: G 245-G249.
- Bataller, R; and Brenner, D.A; (2005):** liver fibrosis. J. clin invest; 115: 209-218.
- Bdosa, P; and Poynard, T; (1994):** The METAVIR cooperation group inter and intra-observer variation in assessment of liver biopsy of chronic hepatitis C. Hepatology; 20 (1): 15-20.
- Bedossa, P; and Poynard, T; (1996):** An algorithm for the grading of activity in chronic hepatitis C. for the METAVIR Cooperative Study Group. Hepatology, 24: 289-293.
- Bedossa, P; Ferlicot, S; Paradis, V; Dargere, D; Bonvoust, F; and Vidaud, M; (2002):** Dystroglycan expression in hepatic stellate cells: role in liver fibrosis. Lab Invest; 82: 1053-1061.

- Bennett, R. G; Mahan, K.J; Gentry-Nielsen, M.J; and Tuma, D.J;** (2005): Relaxin receptor expression in hepatic stellate cells and in cirrhotic rat liver tissue. *Ann. N.Y. Acad. Sci*; 1041: 185-189.
- Berends, M.A.M; Snoek, J; DeJong, E; Krieken, J.H.V; Deknegt, R.J; Vanoijen, M.G.H; Van de kerkhof, P.C.M; and Drenth, J.P.H;** (2007): Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: fibrotest predicts the presence and fibroscan predicts the absence of significant liver fibrosis: *liver Int.* 27 (5): 639-45.
- Bilzer, M; Roggel, F; and Gerbes, A.L;** (2006) : Role of kupffer cells in host defense and liver disease. *Liver international*; 26: 1175-1186.
- Bonacchi, A; Romagnani, P; Romanelli, R.G; Efsen, E; Annunziation, F; Lasagni, L; Francalanci, M; Serio, M; Laffi, G; Pinzani, M; Gentillini, P; and Marra, F;** (2001): Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. *J. Biol. Chem*; 276-: 9945-9954.
- Bonacini, M; Hadi, G; Govindarajan, S; and Lindsay, K.L;**(1997): Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. *Am J. Gastroenterol*; 92:1302.1304
- Borkham-Kamphorst, E; Van Roeyen, C.R; Ostendori, T; Floege, J; Gressner, A.I.M; and Weiskirchen, R;** (2007): Pro-fibrogenic potential of PDGF-D in liver fibrosis. *J. Hepatology*; 46: 1064-1074.

- Braete, F; Dezanger, R; Baekeland, M; Evelyne, C; Smissen, P.V.D; and Wisse, E; (1995):*** Structur and dynamics of the fenestra associated cytoskelton of rat livers sinsoidal endo thelial cell. *Hepatology*; 21: 180.
- Bravo, A.A; Sheth, S.G; and Chopra, S; (2001):*** Liver biopsy, *N. Eng. J Med*; 344: 495-500.
- Bubak, M.E; Porayko, M.K; Krom, R.A.F; and Wiesner, R.H; (1991):*** Complications of liver biopsy in liver transplant patients: increased sepsis associated with choledochojejunostomy. *Hepatology*; 14: 1603-1605.
- Buscarini, L; Fornari, F; Bolondi, L; Colombo, P; Livraghi, T; Magnolfi, F; Rapaccini, G,L; and Salmi, A; (1990):*** Ultrasound-guided fine- needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. *J. Hepatol.*; 11:344.
- Cadranel JF and Philippe M (2002):*** Prothrombin index decrease: a useful and reliable marker of extensive fibrosis. *Eur. J. Gastroenterol. Hepatol.*; 14(10): 1057-1059.
- Cadranel, J.F; Rufat, P; and Degos, F; (2000):*** Practices of liver biopsy in france results of prospective nation wide survey *hepatology*. 32; 477-81.
- Calvaruso, V; Camma, C; Di Marco, V; Maimone, S; Bronte, F; Enea, M; Dardamioni, V; Manousou, P; Pleguezuelo, M; Xirouchakis, E; Attanasio, M; Dusheiko, G; Burroughs, A.D; and Craxi, A; (2009):*** Fibrosis Staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. *Journal of viral hepatitis* Sept. 25: 1-6.

- Carrion, J.A; Navasa, M; Bosch, J; Bruguera, M; ilabert, R; and Forns, X; (2006):*** Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation liver Transplantation; 12: 1791-1798.
- Cassiman, D; and Roskams, T; (2002):*** Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. J. Hepatol.; 37:527-535.
- Castera, L; (2009):*** Transient elastography and other non invasive test to assess hepatic fibrosis in patients with viral hepatitis, Journal of viral hepatitis, 16; 300-314.
- Castera, L; Bernard, P.H; Le Bail, B; foucher, J; Merrouche, W; Cousigou, P; and Deledinghen, V; (2007):*** What is the best non-invasive method for early prediction of cirrhosis in chronic hepatitis C? Prosective comparison between Fibroscan and serum markers (Lok index, APRI, AST/ALT ratio, platelet count and Fibrotest) (abstract). Hepatology; 46- : 156A.
- Castera, L; Brigitle, L.B; Francoise, R.T; Roudot-Thoraval F; Pierre-Henri, B; Juriette, F; Wassil, M; Patric, C; and Victor, D.L; (2009):*** Eary detection in routine clinical practice of cirrhosis and esophageal varices in chronic hepatitis C: Comparison of transient elastography (Fibroscan) with standard laboratory tests and non-invasive scores. Journal of Hepatology; 50 : 59-68.
- Castera, L; Fornx, X; And Albert, A; (2008):*** Non-invasive evaluation of liver fibrosis using transient elastography. Journal of Hepatology; 48:835-847.

- Castera, L; Vergniol, J; Foucher, J; Lebail, B; Chanteloup, E; Haaser, M; Darriet, M; Couziqou, P and Deledinghen, V; (2004):*** Prospective comparison of transient elastography, fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology*; 128: 343-350.
- Caturelli, E; Giacobbe, A; Facciorusion, D; Bisceglia, M; Villani, M.R; Siena, D.A; Fusilli, S; Squililante, M.M; and Andriulli, A; (1996):*** Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rat by routine ultrasound assessment of puncture site. *Am. J. Gastroenterol*; 91: 1318-1321.
- Chan, E.S; Montesinos, M.C; Fernandez, P; Desai, A; Delano, D.L; Yee, H; Ress, A.B; Pillinger, M. H; Chen, J.F; Schwarzschild, M.A; Friedman, S. L; and Crostein, B,N; (2006):*** Adenosine A (2A) receptors play a role in the pathogenesis of hepatic cirrhosis. *Br J Pharmacol*; 148: 1144-1155.
- Coco, B; Oliveri, F; Maina, A.M; Ciccorossi, P; Sacco, R; Colombatto, P; Bonino, F; and Brunetto, M.R; (2007):*** Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transminases. *J, Viral Hepatitis*; 14 : 360-369.

- Colloredo, G; Guido, M; Sonzogni, A; and Leandro, G; (2003):** Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. *J. Hepatol*; 39 (2): 239-44.
- Corpechot, C; El Naggar, A; and Poupon, R; (2006):** Gender and liver: is the liver stiffness weaker in weaker sex? *Hepatology*; 44: 513-514.
- Corpechot, C; El Naggar, A; Paujol-Robert, A; Ziol, M; Wendum, D; Chazouilleres, O; Deledinghen, V; Dhumeaux, D; Marcellin, P; Michel, B; and Poupon, R; (2006):** Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. *Hepatology*;43: 1118 -1124 .
- Coverdale SA, Samarasinghe DA, Lin R and Kench, J; Byth, K; Khan, M.G; Crewe, E; Liddle, C; George, J; and Farrell, G.C; (2003):** Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. *Am. J. Gastroenterol.*; 98(6): 1384-1390.
- Darwish M, Faris R, Clemens J and Rao, M.R; and Edelman, R; (1996):** High seroprvalence of hepatitis A, B, C and D viruses in residents in an Egyptian village in the Nile Delta. A pilot study. *Am. J. Trop. Med. Hyg.*; 54(6): 554-558.
- de Ledinghen, V; Douvin, C; Kettaneh, A; Ziol, M; Roulot, D; Marcellin, P; Dhumeaux, D; and Beaugrand, M; (2006):** Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. *J. Acquir Immune Dcfic Syndr*;41:175-179.

- de Ledinghen, V; LeBail, B; Robouissoux, L; Fournier, D; Foucher, J; Miette, V; Castera, L; Sandrin, L; Merrouche, W; Lavrand, F; and Lamireau, T; (2007):*** liver stiffness measurement in children using fibroscan feasibility study and comparison with fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. *J. of pediatric gastroenterology and nutrition* , 45: 443-50.
- Demetri, G.D; Von Mehren, M; Blanke, C. D; VanDen Abbelle, A.D; Eisenberg, B; Roberts, P.J; Heinrich, M.C; Tuveson, D.A; Singer, S; Janicek, M; Fletcher, J.A; Silverman, S.G; Silberman, S.L; Capdeville, R; Kiese, B; Peng, B; Dinitrijeevic, S; Druker, B. J; Corless, C; Flietcher, C; and Joensuu, H; (2002):*** Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N. Engl. J. Med.*; 347: 472-480.
- Demetris, A.J; and Ruppert, K; (2003):*** Pathologist's persepective on liver needle biopsy size 5 *hepatology*; 39: 275-277.
- Desmet, V; Gerber, M; Hoffnagle, J.H; Mamns, M; and Scheuer, P.T; (1994):*** Classification of chronic hepatitis: Diagnosis, grading and staging, *hepatology*; 19: 1513-1520.
- Ding, X; Saxena, N.K; Lin, S; Amin, X.U; Srinivasea, S; and Anania, F.A; (2005):*** The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. *Am. J. Pathol.*; 166: 1655-1669.
- Dixon, A; Bradley, J; Nunez, D; and Seymour, C; (1987):*** Failure of percutaneous liver biopsy anatomical variation *lancet* 2: 437-439.

- Dooley, S; Hamzai, J; Breitskopf, K; Wiercinska, E; Said, H.M; Lorenzen, J; Diike, P.T; and Gressner, A.M; (2003):** Smad 7 prevents activation of hepatic stellate cells and liver fibrosis in rats. *Gastroenterology*; 125: 178-191.
- Dotter, C.T; (2004):** Catheter biopsy. Experimental technique for transvenous liver biopsy. *Radiology*; 82: 312-314.
- El-Sayed MN, Gomatos PJ, Rodier GR and Wierzba, T.F; Darwish, A; Khashaba, S; and Arthur, R.R; (1996):** Seroprevalence survey of Egyptian tourism workers for hepatitis B virus, HCV, HIV, *Treponema pallidum* infection: association of HCV infection with specific regions of Egypt. *Am J Trop med Hyg*; 55(2): 179-84.
- Fallowfield, J.A; and Iredale, J.P; (2004):** Targeted treatment for cirrhosis. *Expert. Opin. Ther. Targets*; 8: 423-435.
- Fiorucci, S; Antonelli, E; and Morelli, A; (2003):** Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver. *Dig. Liver Dis.*; 35: 61-69.
- Fischer, R; Cariers, A; Reinehr, R; and Haussinger, D; (2002):** Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. *Gastroenterology*; 123: 845-861.
- Fontages, T; Bailly, F; Trepoi, E; Chevallier, M; Muet, M.M; Nalet, B; Beorchia, S; Pillon, D; Moindrot, H, Froissart, B; Slaoui, M; Tinel, X; Pradat, P; and Trepo, C; (2008):** Discordance between biochemical markers of liver activity and fibrosis (actitest) (fibrotest) and liver biopsy in patients with chronic hepatitis C gastroenterol. *Chin Biol*.

- Forbes, S.J; Russo, F.P; Burra, P; Rugge, M; Wright, N.A; and Slison, M.R; (2004):** A significant proportion of myofibroblasts in human liver fibrosis are of bone marrow origin. *Gastroenterology*. 126 (4): 955-963.
- Forns, X; Ampurdanes, S; Liovet, J.M; Aponte, J; Quinto, L; Bauer, M.E; Bruguera, M; Tapias, S.J.M; and Rodes, J; (2002):** Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive mode. *Hepatology*; 36: 986-992.
- Foucher, J; Castera, L; Bernard, P.H; Adhoute, X; Laharie, D; Bertet, J; Couzigou, P; and deledinghen, V; (2006):** Prevalence and factors associated with failure of liver stiffness measurement using fibroscan in a prospective study of 2114 examinations. *Eur J Gastroenterol. Hepatol*; 18: 411-412.
- Frank, C; Mohamed, M.K; Strickland, G.T; Lavanchy, D; Arthur, R.R; Magder, L.S; Elkhoby, T; Abdel-Wahab, Y; Ohn, E.A; Anwar, W; and Sallam, L; (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt *lancet*, 355 (9207): 887-91.
- Fraquelli, M; Rigamonti, C; Casazza, G; Conte, D; Donato, M.F; Ronchi, G; and Colombo, M; (2007):** Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut*; 56: 968-973.
- Friedman, S.L (2008):** Hepatic-Overview. *Toxicology*; 254: 120-129.
- Friedman, S.L; (2000):** Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J. Biol Chem*; 275: 2247-2250.

- Friedman, S.L; (2003):** Liver fibrosis from bench to bedside. J. Hepatol.; 38: S38-S53.
- Friedman, S.L; (2004):** Mechanisms of hepatic fibrosis and therapeutic implication Nat. Clin. Paract. Gastroenterol. Hepatology; 1: 98-105.
- Friedman, S.L; (2007):** Hepatic fibrosis in schiff's diseases of the liver. Edited by Schiff R, Sorrell F and Maddrey c, vol (1), 10th ed. Cha (114): 395-418. Lippincott Williams and wilkings. Wolters Kluwer Company.
- Friedman, S.L; Manton, P; and Munoz, S.J; (2002):** Laboratory metvodes for evaluation of the patients with liver disease. In zkin D, Boyer, T deds. Hepatology aterxt book of liver disease, Philadelphia: samder; 661-708.
- Friedrich-Rust, M; ong, M.F; Hermann, E; Dries, V; Samaras, P; Zeuzem, S; and Sarrazin, C; (2007):** Real-time elastography for non invasive assessment of liver fibrosis in chronic viral hepatitis. AJR. Am. J. Roentgenol. 188: 758-764.
- Friedrich-Rust, M; Ong, M.F; Martens, S; Samaras, P; Zeuzem, S; and Herrman, E; (2008):** Performance of transient elastography for the staging of liver fibrosis. A meta analysis. Gastroenterology; 134: 960-974.
- Ganne-Carrie, N; Ziol, M; De Ledinghen, V; Douvin, C; Marcellin, P; Castera, L; Dhumeaux, D; Trinchet, J. C; and Beaugrand, M; (2006):** Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver disease. Hepatology; 44: 1511-1517.
- Geerts, A; (2001):** History, heterogeneity, developmental biology and functions of quiescent hepatic stellate cells. Semin Liver Dis.; 21: 311-335.

- Giannini, E.G; Zaman, A; Ceppa, P; Mastracci, L; Risso, D; and Testa, R; (2006):** A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. *j. Clin Gastroenterol*; 40: 521-527.
- Gomez-Dominguez, E; Mendoza, J; Rubio, S; Moreno-Monteagudo, J.D; Garcia-Bvey, L; and Moreno-Otero, R; (2006):** Transient elastography: a valid alternative to biopsy in patients with chronic, liver disease, *Aliment pharmacol ther*. 24, 513-518.
- Gressner, A.M; Weiskirchen, R; Breitkopf, K; and Dooley, S; (2002):** Roles of TGF-Beta in hepatic fibrosis. *Front Biosci*; 7: D793-D807.
- Gressner, O.A, Weiskirchen, R; and Gressner, A.M; (2007):** Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. *Clinica Chimica Acta*; 381: 107-113.
- Grigorescu, M; (2006):** Non-invasive biochemical markers of liver fibrosis. *J Gastrointest. Liver Dis.*; 15(2): 149-59.
- Guechot, J; Laudat, A; Loria, A; Serfaty, L; Povpon, R; and Giboudeau, J; (1996):** Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. *Clin Chem*; 42: 558-563.
- Guha N and Iredale JP (2007):** Clinical and diagnostic as peer, of Cirrhosis. Page 619-634. *Textbook of hepatology "from basic science to clinical practice"*. 3rd Edition.
- Guido, M; and Rugge, M; (2004):** Liver biopsy sampling in chronic viral hepatitis. *Semin Liver Dis.*; 24: 89-97.

- Halfon, P; Bourliere, M; and Deydier, R; (2006):** Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibro paca study. *Am J Gastroenterol*; 101: 547-555.
- Hashimoto, E; Lwdwing, J; and Mac Carty, R.L; (1989):** Hepatoportal arteriovenous fistula morphologic features studied after orthotopic liver transplantation hum. *Pathol.* 20: 707.
- Hashmi, A.Z; Hakim, W; Kruglov, E,A; Watanabe, A; Watkins, W; Dranoft, J.A; and Mehal, W.Z; (2007):** Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. *Am J Physiol*; 292: G395-G401.
- Huwart, L; Sempoux, C; and Vicant, E; (2008):** Magnetic resonance elastography for the non-invasive staging of liver fibrosis. *Gastroenterology* 135 (1): 32-40.
- Huwart, L; Sempoux, C; Salameh, N; jamart, J; Annet, L; Sinkus, R; Peeters, F; Terbeek, L.C; Horsmans, Y; and Van Beers, B. E; (2007):** Liver fibrosis non invasive assessment with MR elastography versus Asparatate amino transferase to platelet ratio index. 245: 458-466.
- Ikejima, K; Hajine, H; Mutsuko, Y; Miyoko, H; Tsuneo, K; Yoshiyuki, T; and Nobuhiro, S; (2001):** Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. *Hepatology*; 34: 288-297.
- Iredale, J.P; (2001):** Hepatic stellate cell behavior during resolution of liver injury. *Semin. Liver Dis.*; 21: 427-436.

- Ishak, D; Baptisa, A; Bianchi, L; Callea, F; Degroote, J; Gudat, F; Denk, H; Desmet, V; Korb, G; and Macsween, R. N; (1995):*** Histopathological grading and staging of chronic hepatitis. *J. hepatol*, 22: 696-699.
- Issa, R; Zhon, X; Trim, N; Sadler, H.m; Krane, S; Benyon, C; and Iredale, J; (2003):*** Mutation in collagen I that confers resistance to the action of collagenase results in failure of recovery from CC14-induced liver fibrosis persistence of activated hepatic stellate cells and diminished hepatocyte regeneration. *FASEAJ*; 17: 47-49.
- Kamada, Y; Tamura, S; Kiso, S; Matsumoto, H; Saji, Y; Yoshida, Y; Fukui, K; Maeda, N; Nishizawa, H; Nagaretani, H; Okamoto, Y; Kihara, S; Miyagawa, J; Shinomura, Y; and Matsuzawa, Y; (2003):*** Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. *Gastroenterology*; 125: 1796-1807.
- Kazemi, F; Kettaneh, A; N'Kontchou, G; Pinto, E; Ganne-Carrie, N; Trinchet, J.C; and Beaugrand , M; (2006):*** Liver stiffness measurement selects patient with cirrhosis at risk of bearing large oesophageal varices. *J. Hepatol*; 45:230-235.
- Kelleher, T; MacFarlane, C; and de Ledinghen, V; (2006):*** Risk factors and hepatic elastography (FibroScan) in the prediction of hepatic fibrosis in non-alcoholic steatohepatitis (abstract). *Gastroenterology*;130:A 736.
- Kettaneh, A; Marcllin, P; Douvin, C; Poupon, R; Zioli, M; Beaugrand, M; and Deledinghen, V; (2007):*** Features associated with successrate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients. *Journal hepatology* : 46: 628-634.

- Kim, K.M; Choi; W.B; Park, S.H; Yu, E; Lee, S.G; Lin, Y.S; Lee, H.C; Chung, Y.H; Lee, Y.S; and Such, D.J; (2007):** Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. *J. Gastroenterol.* 42: 382-388.
- Kimberly, L.B (2005):** Percutaneous liver biopsy coated from hand book of gastroenterologic procedure fifth edition (H) .p. 78-83 published by lippincott Williams, wilkins.
- Klein, S; Mittendorfer, B; Eagon, J.C; Patlerson, B; Grant, L; Feirt, N; Seki, E; Brenner, D; Korenblat, K; and Mccrea, J; (2006):** Gastric bypass surgery improves metabolic and hepatic abnormalities associated with non-alcoholic fatty liver disease *Gastroenterology*: 130: 1564-1572.
- Knodell, R.G; Ishak, K.G; Black, W.C; Chen, T.S; Craig, R; Kaplowitz, N; Kiernan, T.W; and Wollman, J; (1981):** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *J. Hepatology*; 1:431-435.
- Koda, M; Matunaga, Y; Kawakami, M; Kishimoto, Y; Suou, T; and Murawaki, Y; (2007):** FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. *Hepatology*; 45: 297-306.
- Konate, A; Reaud, S; and Wuenener, E; (2006):** Liver stiffness measurement by transient elastography predictive factors of accuracy and reproducibility (Abstract) *J. Hepatology*; 44: 5195.

- Kurikawa, N; Suga, M; Kuroda, S; Yamada, K; and Ishikawa, H; (2003):*** An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. *Br. J. Pharmacol*; 139: 1085-1094.
- Lackner, C; Struber, G; Liegl, B; Leible, B; Leibl, S; Ofner, P; Bankuti, C; Baure, B and Stuber, R.E; (2005):*** Comparison and validation of simple non-invasive tests for prediction of fibrosis in chronic hepatitis C. *Hepatology*;41:1376-1382.
- Laharie, D; Zerbib, F; Adhoute, X; Roue-Lahorgue, X; Foucher, J; Castera, L; Rullier, A; Bertet, J; Couzigou, P; Amourett, M; and Deledinghen, V; (2006):*** Diagosis of liver fibrosis by transietelastogrphy (fibroscan) and non-invesive mchtdods in crohn's disease patients treated with metho trexate. *Aliment pharmacal there*, 23 (1): 1621-8.
- Lazar, H; (1978):*** Fractioned liver biopsy needles. *Gastroenterology*; 74:801.
- Lebrec, D; (1996):*** Various approaches to obtaining liver tissue: choosing the biopsy technique. *J. Hepatol.*; 25 (suppl. 1):20.
- Lechuga, C.G; Hernandez-Nazara, Z.H; Hernandez, E; Hernandez, E; Bustamante, M; Desierto, G; Cotty, A; Dharker, N; Choe, M; and Roikind, M; (2006):*** PI3K is involved in PDGF-beta receptor up regulation post-PDGF-BB treatment in mouse HSC. *Am. J. Physiology Gastrointestinal. Liver Physiology*; 291, G1051-G1061.

- Lefrock, J.L; Charles. A; Ellis, C.A; Turchick, J.B; John, K; Zawacki, and Louis, W; (1975):** Transient bacteremia associated with percutaneous liver biopsy. *J. Infect Dis*; 131:S104-S107.
- Leroy, V; Monier, F; Bottari, S; Trocme, C; Sturm, N; Hilleret, M.N; Morel, F; and Zarski, J.P; (2004):** Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. *Am J. Gastroenterol*; 11:476-481.
- Lewin, M; Poujol-Robert, A; Boelle, P.Y; Wendum, D; Lasnier, E; Viallon, M; Guechot, J; Hoeffel, C; Arrive, L; Tubiana, J. M; and Poupon, R; (2007):** Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. *hepatology*. 46: 658-665.
- Lok, A.S; Ghany, M.G; Goodman, Z.D; Wright, E.C; Everson, G.T; Sterling, R.D; Everhat, J.E; Lindsay, K.L; Bonkovsky, H.L; Dibisceglie, A.M; Lee, W.M; and Morishima, C; (2005):** Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. *Hepatology*; 42:282-292.
- Lucidarme, D; Foucher, J; leBail, B; Verginot, J; Castera, L; Duburque, C; Frozy, G; Couzigou, P; Filoche, B; and deledinghen, V; (2009):** Factors of Accuracy of Transient Elastography (fibroscan) for the Diagnosis of Liver Fibrosis in Chronic Hepatitis C. *Hepatology*; 49: 1083-1089.

- Lucidarme, D; Foucher, J; LeBail, B; Verginol, J; Castera, L; Duburque, C; Frozy, G; Couzigou, P; Filoche, B; and deledinghen, V; (2007):** The ratio interquartile range/median value of liver stiffness measurements is a key factor of accuracy of transient elastography (FibroScan) for the diagnosis of liver fibrosis (abstract). *Hepatology*; 46: 318A.
- Macias, J; Giron-Gonzalez, JA, Gonzalez-Serrano, M; Merino, D; Cano, P; Mira, J.A; Yarza, A.A; Morales, J.R; Cabeza, J.M.L; Garcia, J.A; Corzo, J.E; and Pineda, J.A; (2006):** Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus co infected patients by simple non-invasive indexes. *Gut*; 55: 409-414.
- Manning, D.S; and Afdhal, N.H; (2008):** Diagnosis and Quantitation of Fibrosis. *Gastroenterology*; 134: 1670-1681.
- Marcellin, P; de Ledinghen, V; Dhumeaux, D; Barreiro, P; and Carbonero, M.L; (2005):** Non-invasive assessment of liver fibrosis in chronic hepatitis B using Fibroscan (abstract). *Hepatology*; 42: 715A.
- Marin Gabriel, J.C; and Solis-Herruzo, J.A (2009):** Non invasive assessment of liver fibrosis. Serum markers and transient elastography (fibroscan). *Rev. Esp. Enffrm. Dig* 101 (11); 787-799.
- Martin, P; and Friedman, L.S; (2004):** Assessment of liver function and diagnostic studies. Chapter (1) P (1-16). Coated from Hand book of liver disease 2nd edition Philadelphia.

- Masuzaki, R; Tateishi, R; Yoshida, H; Yoshida, H; Sato, S; Kato, H; Kanai, F; Sugioka, Y; Ikeda, H; Shiina, S; Kawabe, T; and Omata, M; (2008):** Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography J. Clin Gastroenterol 42(7): 839-843.
- McHutchison, J.G; Blatt, L.M; de Medina, M; Craig, J.R; Conrad, A; Schiff, E.R; and Tong, M.J; (2000):** Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus interferon study group. J. Gastroenterol. Hepatol. 15: 945-951.
- Melhem, A; Muhanna, N; Bishara, A; Alvarez, C.E; Iian, Y; Bishara, T; Horani, A; Nassar, M; Friedman S.L; and Safadi, R; (2006):** Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatoogy; 45: 60-71.
- Melton, A.C; and Yee, H.F; (2007):** Hepatic stellate cell protrusions couple platelet-derived growth factor-BB to chemotaxis. Hepatology; 45: 1446-1453.
- Mendoza, J; Gomez-Dominguez, E; Moreno-otero, R; and Marugan, M.T; (2006):** Transient elastography as an alternation to liver biopsy. Med Clin (Barc): 126; 220-22.
- Milani, S; Herbst, H; Schuppan, D; Grappone, C; Pellegrini, G; Pinzani, M; Casini, A; Calabro, A; Ciancio, G; Stefanini, F; Ciancio, A.K; and Surrenti, C; (1994):** Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am. J. Pathol.; 144: 528-537.

- Millong, G, Reimann, F.M; Friedrich, S; Fonouni, H; Mehrabi, A; Buchler, M.W; Seitz, H.K; and Mueller, S; (2008):** Extra hepatic cholestasis increase liver stiffness (fibroscan) irrespective of fibrosis *Hepatology*, 48 (5) : 1718-23.
- Mirault, T; Lucidrame, D; Turlin, B; Vandevenne, P; Pierre, G; Ernst, O; and Rose, C; (2008):** Non-invasive assessment of liver biopsies by transient elastography in post transfusional ironover load. *Eur. J. Haematol*; 80 (4): 337-40.
- Morishima, C, Paschal, D.M; Wang, C.C; Yoshihara, C. S;Wood, B.L; Yeo, A.E; Emerson, S.S; Shuhart, M.C; and Gretch. D.R; (2006):** Decreased NK cell frequency in chronic hepatitis C does not affect exvivo cytolytic killing. *Hepatology*; 43: 473-480.
- Murphy, F.R; Issa, R; Zhou, Z; Ratanarajah, S; Nagase, H; Arthur, M.J; Benyon, C; and Iredale, J.P; (2002):** Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. *J. Biol. Chem*; 277: 11069-11076.
- Myers, R.P; De torres, M; Imbert-Bismut, F; Ratziu, V; Charlotte, F; and Poynard, T; (2003):** Biochemical markers of fibrosis in patients with hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. *Dig Dis Sci*; 48:146-153.
- Ngo, Y; Munteanu, M; and Messous, D; (2006):** A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. *Clin Chem*; 52: 1887-1896.

- Nguyen-K.E; and Capron, O; (2006):** Non-invasive diagnosis of liver fibrosis by ultrasonic transient elastography (FibroScan). Eur J. Gastroenterol Hepatol; 18: 1321-1325
- Nicholls, D.G; and Budd, L.S; (2000):** Mitochondria and neuronal survival. Physiol. Rev.; 80: 315- 360.
- Nicolau C, Bianchi L and Vilana R (2002):** Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: diagnosis, screening and intervention. Seminars in US, CT and MRI; 23 :3–18.
- Niiya, M; Uemura, M; Zheng, X.W; Pollak, E.S; Dockal, M; Scheifflinger, F; Wells, R.G; and Zheng, X.L; (2006):** Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cell upon activation in vitro and in vivo. J. Thromb. Haemost; 4: 1063-1070.
- Novo, E; Marra, F; Zamara, E; Bonzo, L.V.D; Caligiuri, A; Cannito, S; Antonaci, C; Colombatto, S; Pinzani, M; and Parola, M; (2006):** Dose dependent and divergent effects of super oxide anion on cell death, proliferation and migration of activated human hepatic stellate cells. Gut; 55: 90-97.
- Oaklcy, F; Trim, N; Constandinou, C.M; and Yew (2003):** Hepatocyt express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am. J. Path; 163: 1849-1858.
- Oberti F, Valsesia E, and Pilette C; (1997):** Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology.; 113:1609–1616
- Ogawa, E; Furusyo, N; Toyoda, K; Takeoka, H; Shigeru, O; Hamada, M; Murata, M; Sawayama, Y; and Hayashi, J; (2009):** Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatology Research; 37 (12): 1002-1010.

- Ono, E; Shiratori, Y; Okudaira, T; Imamura, M; Teratani, T; Kanai, F; Kato, N; Yoshida, H; and Omata, M; (1999):** Platelet count reflects stage of chronic hepatitis C. *Hepatol. Res*; 15: 192-200.
- Parola, M; and Robino, G; (2001):** Oxidative stress-related molecules and liver fibrosis. *J. Hepatol.*; 35: 297- 306.
- Patch, D; (2005):** Liver biopsy chapter 134 coated from clinical gastroenterology and hepatology 1st Edition. Page 987 to 991.
- Piccinnio, F; Sagnelli, E; Pasquale, G; and Giusti, G; (1998):** Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies *J Hepatol.* 2: 165-173.
- Pietrangela, A; (1996):** Metals, Oxidative stress and hepatic fibrogenesis. *Semin. Liver Dis.*; 16: 13-30.
- Pinzani, M. (2000):** Liver fibrosis springet semin immunopathol; 21: 475-490.
- Pinzani, M. (2006):** Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they've hatched. *Gut*; 55 (3): 310-312.
- Pinzani, M; (2002):** PDGF and signal transduction in hepatic stellate cells. *Front. Biosci*; 7 : d 1720-d1726.
- Pinzani, M; (2004):** Pathogenesis of hepatic fibrosis p (121-129). In liver disease from bench to besides. American association for the study of liver diseases. Massachusetts October; 29-30.

- Pinzani, M; and Marra, F; (2001):** Cytokine receptors and signaling in hepatic stellate cells. *Semin Liver Dis* ,21: 397-416.
- Pinzani, M; and Rombouts, K; (2004):** Clinical Liver fibrosis; from the bench to clinical targets. *Digestive and Liver Disease*; 36: 231-242.
- Poynard, T; and Bedossa, P; (1997):** Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study groups. *J. Viral Hepatol*; 4:199-208.
- Poynard, T; Bedossa, P; and Opolon, P; (1997):** Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. *Lancet*; 349: 825-832.
- Poynard, T; Ingiliz, P; Munteanu, M; Lebray, P; Morra, R; Messous, D; Bismut, F.I; Roulot, D; Benhamou, Y; Thabout, D; and Ratziu, V; (2008):** Concordance in a world without a gold standard a new non invasive methodology to improving accuracy of fibrosis markers. *Plus one*; 3 (12) : e 3857.
- Poynard, T; Munteanu, M; Imbert, Bismut, F; Charlotte, F; Thabut, D; Lecalvez, S; Messous, D; Thibault, V; Moussalli, J; and Ratziu, V; (2004):** Prospective analysis of discordant result between biochemical markers and biopsy in patients with chornic hepatitis C *Clin Chem*. 50(8): 1344-55.
- Poynard, T; Ratziu, V; and Bedossa, P; (2000):** Appropriateness of liver biopsy *C.J. Gastro enterol*; 14: 543-548.

- Radaeva, S; Sun, R; Jaruga, B; Nguyen, V.T; Tian, Z; and Gao, B; (2006):** Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. *Gastroenterology*; 130: 435-452.
- Ramalho, L.N; Ramalho, F.S; Zucoloto, S; Junior, C.E.S.O; Correa, F.M; Elias, J; and Magalhees, J.F; (2002):** Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. *Hepatogastroenterology*; 49: 1499-1502.
- Rassouni, F; Amellal, N; Amrani, L; Achour, J; Ahid, S; and Omrani, N; (2009):** Non-invasive assessment of liver fibrosis in chronic hepatitis C. *Arab. Journal, of gastroenterology*. 10 (2) : AB 157.
- Regev, A; Berho, M; Jeffers, L.J; and Lemnox, J; (2002):** Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J. Gastroenterol*; 97: 2614-2618.
- Rigamonti, C; Donato, M.F; Fraquelli, M; Agnelli, F; Ronchi, G; Casazza, G; Rossi, G; and Colombo, M; (2008):** Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation. *Gut* 2008. doi: 10.1136/gut.2007, 135046.
- Rockey, D.C; (2005):** Antifibrotic therapy in chronic liver disease. *Clin. Gastroenterol. Hepatol*; 3: 95-107.
- Rockey, D.C; (2008):** Non-invasive assessment of liver fibrosis and Portal Hypertension with Transient Elastography. *Gastroenterology*; 134: 8-14.
- Rockey, D.C; and Bissell, D.M; (2006):** Noninvasive measures of liver fibrosis. *Hepatology*; 43: 5113-5120.

- Rockey, D.C; Caldwell, S.H; Goodman, Z.D; Nelson, R.C; and Smith, A.D; (2009):** Liver Biopsy. *Hepatology*; 49 (3): 1017-1044.
- Rossi, E; Adams, L; Prins, A; Bulsara, M; Boer, B.D; Garas. G; Macquilian, G; Speers, D; and Jeffrey, G; (2003):** Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. *Clin Chem.*; 49: 450-454.
- Rousselet, M.C; Michalak, S; Dupre, F; Croue, A; Bedossa, P; Saint-Andre, J.P; and Cales. P; (2005):** Sources of variability in histological scoring of chronic viral hepatitis. *Hepatology*; 41: 257-264.
- Saitou, Y; Shiraki, K; Yamanaka, Y; Yamaguchi, Y; Kawakita, T; Yamamoto, N; Sugimoto, K; Murota, K; and Nakano, T; (2005):** Non invasive estimation of liver fibrosis and responce to interferon therapy by serum fibrogenesis marker, YKL-40 in patients with HCV associated liver disease world J. gastroenterol, 11; 476-481.
- Saleh, S.M; Waked, I.A.L; Mohamed, M.S; Alsharawr, A.A; and Abdl-Rahman, M.H; (2010):** Evaluation of biochemical markers and elastography to assess liver fibrosis coated from MD Protocol of Eman Abdelsameea Mahmoud. National liver Institute Menoufiya University.
- Sandrin, L; Fourquet, B; Hasquenoph, JM; Yon, S; Fournier, C; Mal, F; Christidis, C; Ziol, M; Poulet, B; Kazemi, F; Beaugrand, M; and Palau, R; (2003):** Transient elastography: a new non-invasive method for assessment of hepatic fibrosis. *Ultrasound Med. Biol*; 29: 1705-1713.
- Saxena, N.K; Titus, M.A; Ding, X; Floyd, j; Serinivasan, S; Sitaraman, S.Y; and Anania, F.A; (2004):** Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation *FASEB J*; 18: 1612-1614.
- Schuppan, D; (1990):** Structure of extracellular matrix in normal and fibrotic liver collagen and glycoproteins *semin liver Dis*. 10:1.

- Schuppan, D; Ruehl, M; and Somasundaram, R; (2001):** Martix as modulator of stellate cell and hepatic fibrogenesis. *Semin Liver Dis.*; 21: 351-372.
- Sebastiani, G; Vario, A; Guido, M; Noventa, F; Plebani, M; Pistis, R; Ferrari, A; and Alberti, A; (2006):** Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.J. *Hepatology*; 44: 686-693.
- Serejo, F; Costa, A; Oliveira, A.G; Ramahalho, F; Batista, A; and Demoura, M.C; (2001):** Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III. *Dig Sci*; 46:168-1689.
- Sherlock, S; and Dooley, J; (2002):** Anatomy and function; Biopsy of the liver and hepatic cirrhosis. In *Diseases of the liver and Biliary system "11th Edition"*, Blackwell Sc. Publ., Oxford, London, Edinburgh, (1): 1-16; (3): 37-44 and (21): 365-377.
- Shiha, G; Sarin, S. K; Ibrahim, A.E; Omata, M; Kumar, A; Lesmana, L.A; Leung, N; Tozun, N; Hamid, S; Jafri, W; Maryyama, H; Bedossa, P; Pinzani, M; Chawla, Y; Esmat, G; Doss, W; Elzamaty, T; Sakhuja, P; Nasr, A.M; Omar, A; Wai, C.T; Abdallah, A; Salama, M; Hamed. A; Yousry, A; Waked, I; Elsahar, M; Fateen, A, Mogawer, S; Hamdy, H; Elwakil, R and Jury of the APASL consensus development meeting 29 January 2008 on liver fibrosis with and without hepatitis B or C (2009) :** Liver fibrosis : Consensus recommendation of the asian pacific association for the study of the liver (APASL) *hepatol. Int*; 3 (2): 323-333.
- Siller-Lopez, F; Sandoval, A; Salgado, S; Salazer, A; Bueno, M; Gracia, J; Vewra, J; Galvez, J; Ivan, H; Ramox, M; Cordova, E.A; and Borunda, J. A; (2004):** Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis *Gastroenterology*; 126: 1122-1133, discussion 949.

- Stauber, R.E; and Lackner, C; (2007):*** Non-invasive diagnosis of hepatic fibrosis in chronic hepatitis C. *World J. Gastroenterology* 28; 12 (32): 4287-4294.
- Suzuki, A; Angulo, P; Lymp, J; Dave, L; Satomura, S; and Lindor, K; (2005):*** Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. *Liver int*; 25: 779-786.
- Taimr, P; Higuchi, H; Kocova, E; Rippe, R.A; Friedman, S; and Gores, G. J; (2003):*** Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL mediated apoptosis. *Hepatology*; 37: 87-95.
- Takemoto, R; Nakamuta, M; Aoyagi, Y; Fujino, T; Yasutake, K; Koga, T; Yoshimoto, T; Miyahara, T; Fukuizumi, K; Wada, Y; Takami, Y; Saitsu, H; Harada, N; Nakashima, M; and Engogi, M; (2009):*** Validity of Fibroscan values for predicting hepatic fibrosis stage in patients with chronic HCV infection. *Journal of digestive diseases*; 10 (2): 145-148.
- Talwalkar, J.A; Kurtz, D.M; Schoenleber, S.J; West, C.P; and Montori, V.M; (2007):*** Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. *Clin Gastroenterol. Hepatol*; 5(10): 1214-1220.
- Tashashi, Y; Matsuzaki, K; Date, M; Yoshida, K; Furukawa, F; Sugano, Y; Matsusita, M; Himeno, Y; Inagaki, Y; and Inoue, K; (2002):*** Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. *Hepatology*; 35: 49-61.

- Theodossi A, Siegelhalter D, Portmann B; Eddleston, A.L.W.F; and Williams, R; (1983):*** The value of clinical, biochemical, ultrasound and liver biopsy data in assessing patients with liver diseases. *Liver*; 3: 315-326.
- Thomas, D.L; and Seef, L.B; (2005):*** Natural history of hepatitis C. *Clin. Liver Dis.* 9: 383-98.
- Tsukada, S; Westwich, J.K; Ikejima, K; Sato, N; and Rippe, R.A; (2005):*** SMAD and p38 MAPK signaling pathways independently regulate alpha (I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. *J. Biol. Chem*; 280: 10055-10064.
- Vergara, S; Macias, J; Rivero, A; Valencia, G.A; Serrano, G.M; Merino, D; Rios, M.J; Garcia, G. J.A; Camacho, A; Cartes, L.L; Delatorre, J; Viciano, P; and Pineda, J.A; (2007) :*** The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. *Clin Infect Dis*; 45: 969-974.
- Villeneuve, J.P; Bilodeau, M. and Lepage, R; (1996):*** Variability in hepatic iron concentration measurement from needle biopsy specimens. *J. Hepatol*; 25-172.
- Vizzutti, F; Arena, U; Romanelli, R.G; Rega, L; Foschi, M; Colagrande, S; Petrarca, A; Moscarella, S; Belli, G; Zignego, A.L; Marra, F; Laffi, G; and Pinzani, M; (2007):*** Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. *Hepatology*; 45:1290-1297.

- Wai, C.T; Greenson, J.K; Fontana, R.J; Kalbfleisch, J.D; Marrero, J.A; Conjeevaram, H. A; and Lok, A.S; (2003):** A simple noninvasive Index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*; 38: 518-526.
- Westin, J; Lagging, L.M. Wejstal, R; Norkrans, G; and Dhillon, A.P; (1999):** Inter observer study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection *liver* 19: 183-187.
- Whitmire L.F; Galambos J.T; Philips V.M; Sewell, C. W; Erwin, B.C; Torres, W.E; Mcclees, G.R.D; and Bernardino, M.E; (1985):** Imaging guided percutaneous hepatic biopsy: diagnostic accuracy and safety. *J. Clin. Gastroenterol.*; 7:511.
- Wiedmann, M.W; and Caca, K; (2005):** Molecularly targeted therapy for gastrointestinal cancer. *Curr. Cancer Drug Targets*; 5:171-193.
- Williams, E.J; Benyon, R.C; Trim, N; Hadwin, R; Grove, B.H; Arthur, M.J.P; Unemori, E.N; Iredale, J.P; (2001):** Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. *Gut*; 49: 577-583.
- Wong, G.L; Wong, V.W; CHoi. P.C.L; Chan, A.W; Chum, R. h; Chan, H.K; Lau, K.K; Chim, A.M; Yiu, K.K; Chan, F.K; Sung, J.J; and Chan, H.L; (2008):** Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver disease *clinic gastroenterology and hepatology*; 6:

- Wong, J.B; and Koff, R.S; (2000):** Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost effectiveness analysis. *Ann. Intern Med*; 133: 665-675.
- Wong, L; Yamasaki, G; Johnson, R.J; and Friedman, S.L; (1994):** Induction of beta-platelet derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. *J. Clin. Invest*; 94: 1563-1569.
- Yano, M; Kumada, H; Kage, M; Ikeda, K; Shimamatsu, k; Inoue, O; Hashimoto, E; Lefkowitz, J.H; Ludwig, J; and Okuda, K; (1996):** The long term pathological evaluation of chronic hepatitis C. *Hepatology*; 23:1334-40.
- Yoneda, M; Mawatori, H; and Fujita, K; (2008):** Non invasive assessment of liver fibrosis by measurement of stiffness in patients with non alcoholic fatty liver disease (NAFLD). *Digestive and liver diseases*; 40: 371-378.
- Yoon, K.T; and Hyub Han, K. (2008):** New diagnostic method for liver fibrosis and cirrhosis *intervirology*, 51: 11-16.
- Yoshiji, H; Noguchi, R; Kuriyama, S; Ikemaka, Y; Yoshil, J; Yanase, K; Nomisaki, T; Kitade, M; Masaki, T; and Fukui, H; (2005):** Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. *Am. J. Physiol. Gastrointest. Liver Physiol*; 288: G907-G913.
- Zakaria, N; Knisely, A; Portmann, B; Vergani, G. M; Wendon, J; Arya, R; and Devlin, J: (2003):** Acute sickle cell hepatopathy represent a potential contraindication for percutaneous liver biopsy. *Blood*; 101: 101-103.

- Zakim, D; and Boyer, T.D; (1996):*** Fibrosis: representative molecular elements, a basic concept and emerging targets for suppressive treatment (15): 465-498, Hepatic fibrosis and cirrhosis (16): 506-520 and Evaluation of liver function (28): 782-825. In: Hepatology. A text-book of Liver Disease, 3rd ed., Library of Congress, USA.
- Ziol, M; Handra-Luca, A; Kettaneh, A; Christidis, C; Mal, F; Dazemi, F; Deledinghen, V; Marcellin, P; Dhumeaux, D; Trinchet, J. C; and Beaugrand, M; (2005):*** Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Heptology*; 41 : 48-54.
- Zois, C.D; Baltayiannis, G.H; Karayiannis, P; and Tslanos, E.V; (2008):*** systematic review; hepatic fibrosis-regression with therapy *Aliment Pharmacol. Ther*; 28: 1175-1187.